Early De Novo Bladder Malignancy in a Kidney Transplant Recipient (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO1045; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Case Description A 79-year-old man underwent a preemptive living donor kidney transplant with basiliximab induction and was maintained on tacrolimus and mycophenolate...There was no history of cyclophosphamide exposure/ BK polyomavirus infection...Immunosuppression was lowered, and he was treated with intravesical gemcitabine and docetaxel, achieving good response while maintaining stable allograft function...However, given the rapid progression of this tumor, we emphasize the need for risk stratification of the screening process. Additionally emerging immunotherapies pose a new challenge for prevention of allograft rejection."
Clinical • Bladder Cancer • Diabetes • Gastrointestinal Disorder • Genito-urinary Cancer • Gynecology • Infectious Disease • Metabolic Disorders • Musculoskeletal Pain • Oncology • Solid Tumor • Transplant Rejection • Transplantation • Type 2 Diabetes Mellitus • Urothelial Cancer
|
|
Ujala Nasr; Prashamsa Shenoy
|